These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 33849028)

  • 1. The Kidney-Heart Connection in Obesity.
    García-Carrasco A; Izquierdo-Lahuerta A; Medina-Gómez G
    Nephron; 2021; 145(6):604-608. PubMed ID: 33849028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cellular apoptosis in the cardiorenal axis.
    Virzì GM; Clementi A; Ronco C
    Heart Fail Rev; 2016 Mar; 21(2):177-89. PubMed ID: 26852141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kidney and heart interactions during cardiorenal syndrome: a molecular and clinical pathogenic framework.
    Napoli C; Casamassimi A; Crudele V; Infante T; Abbondanza C
    Future Cardiol; 2011 Jul; 7(4):485-97. PubMed ID: 21797745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiorenal Syndrome: Pathophysiology.
    Kumar U; Wettersten N; Garimella PS
    Cardiol Clin; 2019 Aug; 37(3):251-265. PubMed ID: 31279419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levels of Proinflammatory Cytokines, Oxidative Stress, and Tissue Damage Markers in Patients with Acute Heart Failure with and without Cardiorenal Syndrome Type 1.
    Virzì GM; Breglia A; Brocca A; de Cal M; Bolin C; Vescovo G; Ronco C
    Cardiorenal Med; 2018; 8(4):321-331. PubMed ID: 30205401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vasculopathy in the setting of cardiorenal syndrome: roles of protein-bound uremic toxins.
    Guo J; Lu L; Hua Y; Huang K; Wang I; Huang L; Fu Q; Chen A; Chan P; Fan H; Liu ZM; Wang BH
    Am J Physiol Heart Circ Physiol; 2017 Jul; 313(1):H1-H13. PubMed ID: 28411233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Range of adiposity and cardiorenal syndrome.
    Pazos F
    World J Diabetes; 2020 Aug; 11(8):322-350. PubMed ID: 32864046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathogenesis and treatment of the cardiorenal syndrome: Implications of L-arginine-nitric oxide pathway impairment.
    Rajapakse NW; Nanayakkara S; Kaye DM
    Pharmacol Ther; 2015 Oct; 154():1-12. PubMed ID: 25989232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [INTERRELATIONS BETWEEN MICROALBUMINURIA AND RENAL FUNCTION WITH CONTRACTILE ABILITY OF LEFT VENTRICLE IN CARDIORENAL SYNDROME PATIENTS].
    Minasyan A; Gareginyan N
    Georgian Med News; 2015 Oct; (247):34-8. PubMed ID: 26483371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apela inhibits systemic and renal inflammatory reactions in mice with type I cardiorenal syndrome.
    Jin L; Li Q; Li J; Pan Y; Zou J; Wu X; Wang Z
    FASEB J; 2021 Oct; 35(10):e21907. PubMed ID: 34516679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased risk of cardiovascular complications in chronic kidney disease: a possible role of leptin.
    Korolczuk A; Dudka J
    Curr Pharm Des; 2014; 20(4):666-74. PubMed ID: 23688007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cardiometabolic and cardiorenal syndromes interactions in Algerian diabetic-hypertensive patient: interest of predictive multi-biomarkers strategy to renal dysfunction].
    Zoubiri H; Kacimi G; Haffaf el M; Oudjit B; Adjroud N; Koceir EA
    Ann Biol Clin (Paris); 2015; 73(4):443-53. PubMed ID: 26411911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heart-kidney crosstalk and role of humoral signaling in critical illness.
    Virzì G; Day S; de Cal M; Vescovo G; Ronco C
    Crit Care; 2014 Jan; 18(1):201. PubMed ID: 24393300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heart-kidney interactions: mechanistic insights from animal models.
    Liu S
    Am J Physiol Renal Physiol; 2019 May; 316(5):F974-F985. PubMed ID: 30838876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiorenal syndrome type 5: clinical presentation, pathophysiology and management strategies from the eleventh consensus conference of the Acute Dialysis Quality Initiative (ADQI).
    Mehta RL; Rabb H; Shaw AD; Singbartl K; Ronco C; McCullough PA; Kellum JA
    Contrib Nephrol; 2013; 182():174-94. PubMed ID: 23689662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiorenal syndrome type 1: pathophysiological crosstalk leading to combined heart and kidney dysfunction in the setting of acutely decompensated heart failure.
    Ronco C; Cicoira M; McCullough PA
    J Am Coll Cardiol; 2012 Sep; 60(12):1031-42. PubMed ID: 22840531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathophysiology of cardiorenal syndrome in decompensated heart failure: role of lung-right heart-kidney interaction.
    Guazzi M; Gatto P; Giusti G; Pizzamiglio F; Previtali I; Vignati C; Arena R
    Int J Cardiol; 2013 Nov; 169(6):379-84. PubMed ID: 24182905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular and Genetic Mechanisms Involved in the Pathogenesis of Cardiorenal Cross Talk.
    Virzì GM; Clementi A; Brocca A; de Cal M; Ronco C
    Pathobiology; 2016; 83(4):201-10. PubMed ID: 27096747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Organ damage and cardiorenal syndrome in acute heart failure].
    Casado Cerrada J; Pérez Calvo JI
    Med Clin (Barc); 2014 Mar; 142 Suppl 1():26-31. PubMed ID: 24930080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipopolysaccharide in systemic circulation induces activation of inflammatory response and oxidative stress in cardiorenal syndrome type 1.
    Virzì GM; Breglia A; Castellani C; Ankawi G; Bolin C; de Cal M; Cianci V; Angelini A; Vescovo G; Ronco C
    J Nephrol; 2019 Oct; 32(5):803-810. PubMed ID: 31006081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.